Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Avadel Pharmaceuticals PLC
Free Cash Flow
Avadel Pharmaceuticals PLC
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Free Cash Flow
-$46.9m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-14%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Free Cash Flow
$244.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
19%
|
CAGR 10-Years
-11%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Free Cash Flow
$1.3B
|
CAGR 3-Years
23%
|
CAGR 5-Years
18%
|
CAGR 10-Years
23%
|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Free Cash Flow
-$26.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Free Cash Flow
-$42.3m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-171%
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Free Cash Flow
€156.8m
|
CAGR 3-Years
237%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
9%
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Free Cash Flow?
Free Cash Flow
-46.9m
USD
Based on the financial report for Dec 31, 2024, Avadel Pharmaceuticals PLC's Free Cash Flow amounts to -46.9m USD.
What is Avadel Pharmaceuticals PLC's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-14%
Over the last year, the Free Cash Flow growth was 63%. The average annual Free Cash Flow growth rates for Avadel Pharmaceuticals PLC have been 15% over the past three years , -4% over the past five years , and -14% over the past ten years .
You don't have any saved screeners yet